AmPEG6C2-Aur0131 was efficacious even when conjugated at DAR2 (ADC 510) in MOLP-8 xenografts, a MM model resistant to SoC bortezomib and anti-CXCR4 antibodies, in spite of bearing high CXCR4 surface expression36 (Fig. 3c,d, Supplementary Fig. 3g, Supplementary Table 2). Here, CXCR4 is linked to Miyoshi myopathy.